.jpg?#)
BiomX’s phage therapy BX211 succeeds in Phase 2 diabetic bone infection study
BiomX’s antibacterial virus candidate has reduced the size of foot ulcers in patients with diabetic bone infection enrolled in a mid-stage trial. The finding could strengthen the company’s case for an approach that it says ...
BiomX’s antibacterial virus candidate has reduced the size of foot ulcers in patients with diabetic bone infection enrolled in a mid-stage trial. The finding could strengthen the company’s case for an approach that it says ...
